The Holy Grail for the majority of physician-scientists is for their work to translate into something beneficial for human health.
As the largest hospital in the United States devoted entirely to clinical research, the Clinical Center of the NIH (Figure 1 ) is the place where many have reached this goal. The Albert and Mary Lasker Foundation is honoring the Clinical Center of the NIH with the 2011 Mary Woodard Lasker Award for Public Service for its many years of service as a model research hospital that provides highquality patient care; enables rapid translation of laboratory observations into new, innovative approaches for diagnosing, treating, and preventing disease; and trains thousands of physician-scientists who lead the way in translational biomedical research. when the Clinical Center first opened, the National Cancer Institute (NCI) is the biggest user of the Clinical Center - in June 1953, the NCI used 35 of 150 beds, and it currently runs almost one-third of ongoing projects. Although the main job of Clinical Center staff is to facilitate the projects run by researchers at the other NIH Institutes and Centers, they also do their own research, and Clinical Center employees run 6% of current projects. The staff of the Clinical Center provides core services such as anesthesiology, rehabilitation, and radiology; the surgeons and physicians are employed by the Institutes and Centers themselves. The Clinical Center also has a state-of-the-art pharmacy that has a good manufacturing practices (GMP) facility in which customized investigational drug formulations can be manufactured for the many first-in-human clinical trials conducted at the Center; among the projects currently underway at the Clinical Center, 45% are clinical trials, and of these, 90% are first-in-human phase I or II studies; the remaining 55% of projects are natural history studies of disease pathogenesis. Another resource available to researchers using the Clinical Center is its GMP cell processing facility, which can generate large numbers of bone marrow-derived and mesenchymal stem cells for clinical use. According to John I. Gallin (Figure 2) , the current Director of the Clinical Center, who spoke with the JCI recently, the facility also has the potential to generate embryonic stem cells and induced pluripotent stem cells for clinical studies, if federal go-ahead for such projects is granted.
America's research hospital

Patients as partners
In his address to the collected dignitaries upon laying the cornerstone of the Clinical Center on June 22, 1951, President Harry S. Truman said, "Medical care is for the people and not just for the doctors - and the rich. Our objective must be to make the best modern medical care available to more and more people" (2 Figure 3 ). Today, patients come to the Clinical Center not just from all parts of America, but from all around the world. Importantly, the researchers facilitate the travel of many of the patients to the Clinical Center. This extensive geographical reach, with resources to help patients travel, is a key factor in the success of the Clinical Center according to Gallin. It means that researchers can form large cohorts of patients, even if the disease they are studying is a rare condition. Currently, researchers working at the Clinical Center are studying almost 400 different rare diseases, which are usually defined as those with a prevalence of fewer than 200,000 affected individuals in the United States.
Only patients with a precise kind or stage of illness under investigation by an NIH researcher are admitted to the Clinical Center for treatment. Once there, however, they receive state-of-the-art care at no cost. Family members also have access to a tremendous number of essential resources. The Edmond J. Safra Family Lodge provides the families of adult patients with a homelike place to stay, while the Children's Inn is a home away from home where sick children and their families can stay together during treatment. The Clinical Center also has a school with grades kindergarten through high school to assist children who need to stay for prolonged periods.
It is the partnership with the patients that makes the Clinical Center an amazing place to work, Harvey Alter, Chief of Clinical Studies and Associate Director of Research in the Department of Transfusion Medicine at the Clinical Center, told the JCI recently. Alter joined the Department of Transfusion Medicine in 1969 and has been there ever since. Among the many things Alter's research has led to is the cleansing of the American blood supply of hepatitis viruses - work that was honored with the 2000 Albert Lasker Clinical Medical Research Award. However, Alter's passion is his patients, some of whom he has been following for 30 years. He told the JCI that the atmosphere at the Clinical Center is unlike that anywhere else because it enables researchers to build unique doctor/patient relationships, practicing old-time medicine with new technologies. Alter said, "The ethos at the Clinical Center makes it possible to study patients as long as you need to; you don't have to rush them out of the door because they are not a source of income, as they are at other hospitals around the country." This, for him, makes the patients partners in his research, and he and his team recently organized a 30th "birthday" party for a patient they have followed for 30 years - from the point he became infected with a hepatitis virus as a result of a blood transfusion until the present day. Alter says he has learned so much from this patient, and he continues to do so as stored samples taken over the years are continually being tested with new techniques as they are developed, adding, "How can I consider him anything other than a research partner?"
Training the nation's clinical researchers
At the Clinical Center, there are currently clinical research training initiatives for nearly every level of career development, from a summer internship program for high school students to a sabbatical program for experienced researchers. This plethora of programs is key to the Clinical Center's mission to train the current and next generations of clinical researchers. Training has been a core aspect of the Clinical Center since it opened, and with 8% of current deans of medicine in the United States having been trained at the Clinical Center, it is clear that the programs have been a huge success.
The NIH Associate Training Program began in 1953 with only 15 fellows. However, word soon spread that it provided physicians interested in clinical research with a way to avoid the draft: service in the uniformed Commissioned Corps of the Public Health Service (PHS) provided a means for physicians to fulfill their military obliga- Among the Clinical Center patients they studied during their training were a brother-sister pair with excessively high levels of LDL in their blood, severe atherosclerosis, and a propensity for heart attacks at a young age (a condition later named homozygous familial hypercholesterolemia). Upon leaving the NIH, Brown and Goldstein established a research program at the University of Texas Southwestern Medical School aimed at understanding how the body normally controls the level of cholesterol in the blood and why the level was so high in the children they had seen at the Clinical Center. Brown has said, "If we hadn't seen those children at NIH, we would have never known about this illness, and we would have never worked on the problem" (3).
Today, the Clinical Center has a curriculum designed by Gallin of three courses in clinical research. Last year, using long-distance learning techniques, these courses were taught to 3,000 students in 16 countries and on 5 continents. Gallin and other faculty members have also taken the Clinical Center courses to developing countries, teaching a five-day version of the course "Introduction to the Principles and Practice of Clinical Research" in person at several locations in China and at the University of Ibadan, Nigeria (Figure 4 ). Gallin says that expanding the Clinical Center training programs beyond the confines of the NIH is a big step and a key part of his vision to make it a resource for those interested in clinical research throughout the world. and Li. Emil (Tom) Frei and Emil (Jay) Freireich were developing chemotherapeutic treatments for children with acute lymphocytic leukemia. When they started their work, a diagnosis of leukemia was a death sentence, but after trying many combinations of drugs, Frei and Freireich came upon a combination of four (vincristine, methotrexate, mercaptopurine, and prednisone) that induced a 90% complete remission rate. Later work by Frei and Freireich as well as others has led to an overall survival rate in children with acute lymphocytic leukemia treated with chemotherapy of almost 80%.
Roscoe Brady and Elizabeth Neufeld were awarded the 1982 Albert Lasker Clinical Medical Research Award for their work on genetic diseases, much of which they conducted at the Clinical Center in the 1960s. Brady and colleagues identified the enzyme defects responsible for the lysosomal storage diseases Gaucher disease, NiemannPick disease, Fabry disease, and Tay-Sachs disease, while Neufeld and colleagues identified the enzyme defects responsible for several of the lysosomal storage diseases known collectively as mucopolysaccharide storage disorders. The work of Brady and Neufeld provided the foundation for the development of assays to diagnose patients with these conditions; strategies to perform prenatal screening for these diseases; and, in the case of Gaucher disease, an effective enzyme replacement therapy.
The Clinical Center also played a key role during the HIV/AIDS public health crisis, awareness of which began emerging there in 1981 - the Center's first patient with AIDS was admitted on June 16, 1981, by NCI investigator Thomas Waldmann, who had no idea why the patient was experiencing multiple infections and a dangerously low white blood cell count. Thus far, more than 350 patients have come to the Clinical Center as part of the Undiagnosed Diseases Program. However, this is just a small percentage of the total number of cases referred to the program, 4,000. A multidisciplinary team, headed by Gahl, meets every two weeks to discuss in exquisite detail all the patients recently referred to the program. Any patient with a longstanding medical condition that has eluded diagnosis by a referring physician can be considered to have an undiagnosed disease and is of possible interest to the program.
Earlier this year, the first disease unraveled through the Undiagnosed Diseases Program was reported in the New England Journal of Medicine (4) . Members of two families with an adult-onset condition associated with progressive and painful arterial calcification in arteries below the waist and in the joints of the hands and feet were admitted to the Clinical Center. One of the families was consanguineous, with five siblings affected by the disease that spared their parents. This led to the hypothesis that the condition could be inherited in an autosomal recessive manner and to SNP analysis to identify regions of the genome for which all five affected siblings were homozygous and both parents heterozygous. Only one such region emerged from the SNP analysis. Genome sequencing of three genes in the region revealed a homozygous nonsense mutation in exon 3 of the 5′-nucleotidase, ecto (NT5E) gene, which encodes CD73, as the cause of disease in the five affected siblings in this family. Nonfunctional mutations in NT5E were also found in the affected individuals of the second family and of an affected individual in Europe.
Gallin told the JCI that the success of the Undiagnosed Disease Program highlights for him one of the key reasons that the Clinical Center exists, which is "to provide hope to patients, especially those with undiagnosed diseases and those with diseases challenging to treat." He hopes that the program will provide a model that other institutions around the country will emulate, such that a series of regional programs that interact with each other might emerge.
Moving forward, another need that has been exposed by the advent of the Undiagnosed Diseases Program is long-term patient care. As Gallin told the JCI, the Clinical Center cannot accommodate all the patients chronically, and the Undiagnosed Diseases Program is actively looking for partners to address this need.
Changes afoot
The Clinical Center has always been intended to be a global resource for patients and, through the publication of intramural findings, clinical researchers. However, because of its focus on facilitating only intramural research, its reach has been somewhat limited. Following thorough assessment of the Clinical Center in 2010, it was recommended that the Clinical Center expand its scope to become more of a resource for external clinical research communities. While some programs involving collaborations with extramural investigators have been active for a few years, Gallin told the JCI that he sees this as the biggest change that the Clinical Center will undergo in the coming years. However, he is adamant that such changes will not diminish, and will in fact enhance, the position of the Clinical Center as a "monument to clinical research and a beacon to provide hope to patients."
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